Berberine Can Target the VEGFR2/ERK Pathway to Inhibit Angiogenesis in Glioblastoma Xenografts

Huaze Liu

2022

Abstract

The purpose of this article is to investigate the concrete effect of berberine on angiogenesis of glioblastoma cells. The glioblastoma is the most malignant cancer with high mortality and it is also difficult to treat with modern medical methods. The fractionated radiotherapy, interstitial radiotherapy or stereotactic radiosurgery all have unstable effects on tumor. Previous study has reported that berberine can inhibit the angiogenesis in glioblastoma xenografts through targeting the VEGFR2/ERK pathway. And this study investigates the concrete effect of berberine on angiogenesis of glioblastoma cells. In the hypothetical experiment, we will treat glioblastoma xenograft mice with increasing amounts of injected Berberine (0, 0.1, 0.3, 1 mg/ml, 10 mg/ml) for 0 min, 1 day, 7 days, 2 weeks and then measure tumor weight and size, and perform confocal microscopy/ immunohistochemistry (IHC) for VEGFR2, or phospho-ERK and unphosphorylate ERK. The experiment will also measure VEGFR2, phosphorylate ERK, unphosphorylate ERK by western blot. Positive control is Temozolomide treatment.There are three most possible results: (1) Berberine inhibit the angiogenesis of glioblastoma cells in both in vitro and in vivo cell lines; (2) berberine can only inhibit the angiogenesis of glioblastoma cells in in vitro cell cultures; (3) berberine only inhibit the angiogenesis of glioblastoma cells in determined human and murine glioblastoma. In conclusion, the results of this study will provide important information for future clinical trials of berberine treatment. Future studies should focus on improving in vivo delivery methods, finding more inhibitors of the angiogenic pathway in glioblastoma, and exploring in detail the specific mechanisms of berberine.

Paper Citation

in Harvard Style

Liu H. (2022). Berberine Can Target the VEGFR2/ERK Pathway to Inhibit Angiogenesis in Glioblastoma Xenografts. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 951-956. DOI: 10.5220/0011313500003443

in Bibtex Style

@conference{icbeb22,
author={Huaze Liu},
title={Berberine Can Target the VEGFR2/ERK Pathway to Inhibit Angiogenesis in Glioblastoma Xenografts},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={951-956},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011313500003443},
isbn={978-989-758-595-1},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - Berberine Can Target the VEGFR2/ERK Pathway to Inhibit Angiogenesis in Glioblastoma Xenografts
SN - 978-989-758-595-1
AU - Liu H.
PY - 2022
SP - 951
EP - 956
DO - 10.5220/0011313500003443